Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6452W HIGH $1.80
Volume
963.82 K
Value Traded
1.11 M
Short % Float
1.93%
Days to Cover
1.1
+13.57%Week
+41.96%1 Month
+51.43%3 Month
+80.68%6 Month
-93.88%5 Year
-93.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
164.10 M
EPS (TTM)
-0.35
P/E Ratio
-
Ent. Value
58.41 M
Total Shares
103.21 M
Float Shares
94.82 M
Insiders
8.12%
Institutions
64.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MXCT Catalyst Timeline
Dated clinical, regulatory and corporate events for MaxCyte, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MaxCyte, Inc.
163Total events
4Upcoming
46Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Quarterly UpdateCorporate
MaxCyte reports preliminary Q3 2026 revenue of ~$8.1M core business, up 26% YoY
▲Quarterly UpdateCorporate
MaxCyte reports preliminary Q3 2026 core business revenue of ~$8.1M, up 26% YoY
●Management ChangeCorporate
MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer
▲Product LaunchPost-Market
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE off-target nomination assays
▲Milestone PaymentCorporate
$1.0 million milestone revenue received from an SPL partner in Q3 2026
▲Partnership / LicenseCorporate
VectorBuilder partners with MaxCyte to advance clinical-grade cell engineering
◆Management ChangeCorporate
CFO Douglas Swirsky to transition from role in first half of 2026
▲First Patient DosedTrial
SPL clinical customer began dosing patients in a registrational study in Q1 2026
▲Runway Guidance UpdateCorporate
MaxCyte raises FY2026 revenue guidance to ~$34M from $30-32M
●Runway Guidance UpdateCorporate
Reiterated full year 2025 revenue guidance; expects $152M-$155M cash by year-end
◆Quarterly UpdateCorporate
Q3 2025 earnings call to provide restructuring financial impact and outlook
▲Partnership / LicenseCorporate
Two new SPL agreements announced with Adicet Bio and Anocca AB
▲Partnership / LicenseCorporate
Strategic collaboration between MaxCyte and Ori Biotech to improve manufacturing efficiencies for autologous cellular therapies
●Restructuring LayoffsCorporate
Considering cancellation of AIM listing to concentrate on Nasdaq
●Quarterly UpdateCorporate
Audited financial statements for Q4 and FY2024 expected to be released
▲Partnership / LicenseCorporate
MaxCyte signs strategic platform license with TG Therapeutics
▲IND Clearanceazer-celIND
FDA clearance of IND for azer-cel in progressive MS
progressive forms of multiple sclerosissource ↗
●Runway Guidance UpdateCorporate
Updated 2025 cash guidance: expects at least $155 million in total cash, cash equivalents and investments by end of 2025
Past FDA Catalysts and PDUFA Decisions
How MXCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MXCT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ahuja ParmeetOfficer (Chief Financial Officer) | Grant/Award | 187,500 187,500 held | $0.00 | 04/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MXCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.7 % (-63.2 %) | 5.90 M | 1.89 M | -59.92% ( -2.83 M) |
MXCT Institutional Ownership Trends
MXCT Short Interest
Shares sold short, counted twice a month.
1.93%
Short % of Float
of tradable shares sold short
1.8M
Shares Sold Short
+68.1% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MXCT ranks across every disease it competes in
Competitive Position is a premium feature
See how MXCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMXCT News
MXCT▲ +11%on this news
MaxCyte to Participate in Three Upcoming Investor Conferences
MaxCyte, Inc. announced its participation in three upcoming investor conferences. The events include a fireside chat at the Stifel 2026 Healthcare Conference, the Craig-Hallum Alpha Select Conference, and the Stephens Annual Investment Conference. A live webcast will be available on their investor relations website.
Read more →MXCT▲ +29.6%on this news
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte, Inc. reported preliminary revenue of approximately $8.1 million for Q3 2026, marking a 26% increase from the previous year. The company raised its full-year revenue guidance to around $34 million, driven by strong core business performance and strategic partnerships. MaxCyte's CEO expressed optimism about the company's growth trajectory and ongoing support for clinical programs.
Read more →MXCTMaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MaxCyte, Inc. has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. With nearly 25 years of experience in corporate development and innovation, he aims to enhance MaxCyte's growth. His previous roles include leadership positions at Danaher Corporation and GE Healthcare. Kapileshwar's expertise is expected to drive the company's next chapter in cell therapy advancements.
Read more →MXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. announced the granting of inducement awards to Sidharth Kapileshwar, who has joined as Senior Vice-President, Chief Corporate Development Officer. The awards include stock options for 220,000 shares and RSUs for 110,000 shares, aimed at incentivizing his employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCT▲ +9.4%on this news
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
MaxCyte has launched two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, to enhance the assessment of genome editing therapies. These assays, part of the SeQure service, provide sensitive identification of off-target sites for adenine and cytosine base editors. The new offerings aim to help developers meet regulatory expectations and improve safety assessments in therapeutic development.
Read more →MXCT▲ +9.4%on this news
MaxCyte Reports Second Quarter 2026 Financial Results
MaxCyte reported a total revenue of $7.3 million for Q2 2026, which includes $6.5 million from core operations. The company reiterated its full-year guidance and highlighted a strategic partnership with Genentech. Despite a decrease in revenue compared to the previous year, MaxCyte noted a reduction in net losses and ongoing efforts to return to revenue growth.
Read more →MXCT▲ +5.1%on this news
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MaxCyte has announced a technology license partnership with Genentech to enhance cell therapy development. The agreement grants Genentech access to MaxCyte's ExPERT GTx platform and other technologies, facilitating cell engineering applications. This collaboration aims to support multiple programs and streamline workflows from research to manufacturing, showcasing MaxCyte's expertise in cell therapies.
Read more →MXCTMaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MaxCyte, Inc. will release its financial results for Q2 2026 on August 12, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results. Investors are encouraged to register online in advance for the call, which will also be available via webcast.
Read more →MXCTVectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
VectorBuilder has announced a partnership with MaxCyte to enhance clinical-grade cell engineering. This collaboration aims to leverage both companies' strengths in cell engineering technologies. Further details on the specific objectives or expected outcomes of this partnership were not provided in the announcement.
Read more →MXCT▲ +24.1%on this news
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte reported a total revenue of $9.7 million for Q1 2026, including $6.2 million in core revenue. The company reiterated its full year revenue guidance of $30-32 million and announced a $10 million share repurchase program. CEO Maher Masoud expressed confidence in their performance and growth strategy, highlighting advancements in their SPL portfolio.
Read more →MXCT▼ -6.8%on this news
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte, Inc. will announce its financial results for Q1 2026 on May 12, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results. Investors are encouraged to register online for the call, which will also be available via webcast. MaxCyte focuses on cell-engineering technologies to support therapeutic development.
Read more →MXCT▲ +5.9%on this news
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2026
MaxCyte, Inc. has announced the granting of inducement awards to Parmeet Ahuja, its new Chief Financial Officer. The awards include stock options for 375,000 shares and RSUs for 187,500 shares, aimed at incentivizing Ahuja's long-term commitment to the company. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCT▼ -6.8%on this news
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
MaxCyte, Inc. reported its financial results for Q4 and full year 2025, revealing total revenues of $7.3 million for the fourth quarter and $33.0 million for the year. The company anticipates revenue of $30-32 million for 2026, despite facing challenges from a major customer. MaxCyte has made strides in reducing cash burn and expanding its SPL portfolio, positioning itself for potential growth in the cell therapy market.
Read more →MXCTMaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Ahuja succeeds Douglas Swirsky and brings over 20 years of finance leadership experience from Agilent Technologies. CEO Maher Masoud expressed confidence in Ahuja's ability to enhance financial operations and support the company's growth strategy.
Read more →MXCT▲ +5%on this news
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
MaxCyte has launched ExPERT DTx™, a 96-well electroporation platform designed to improve research and drug discovery. This modular system allows for high throughput transfection with minimal cellular stress, streamlining workflows and enhancing experimental consistency. The platform features advanced software for remote experiment design, maximizing efficiency in laboratory settings.
Read more →MXCT▲ +5%on this newsshared move
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MaxCyte, Inc. will announce its fourth quarter and full year 2025 financial results on March 24, 2026. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register online for the call, which will also be available via a live and archived webcast.
Read more →MXCTMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results ROCKVILLE, MD
MaxCyte, Inc. has announced its preliminary unaudited financial results for the fourth quarter and full year 2025, indicating an expected total of approximately $155.6 million in cash and investments. Despite facing a challenging year, the company reported core revenue in line with guidance and anticipates returning to revenue growth in the latter half of 2026. CEO Maher Masoud emphasized the company's efforts to streamline operations and enhance cost structures for efficient growth going forward.
Read more →MXCTMaxCyte Announces Planned CFO Transition in 2026
MaxCyte, Inc. has announced that CFO Douglas Swirsky will transition from his role in the first half of 2026. The company is initiating a search for his successor, and Swirsky will remain in his position until a replacement is appointed. He will continue to support the company in an advisory capacity post-transition. The leadership change is not expected to disrupt operations or strategic priorities.
Read more →MXCTMaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
MaxCyte, Inc. reported its third quarter 2025 financial results, indicating a 16% decrease in total revenue compared to the previous year. The company reiterated its revenue guidance for 2025 and highlighted an operational restructuring aimed at cost reduction and long-term growth. Despite a challenging environment, MaxCyte remains committed to its strategic initiatives and partnerships.
Read more →About MaxCyte, Inc.
Headquarters9713 KEY WEST AVENUE,, ROCKVILLE, MD, 20850
BIOPHARMAWATCH ELITE PLUS
Trade the next MXCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime